Literature DB >> 32301033

One-pot sequential coupling reactions as a new practical protocol for the synthesis of unsymmetrical 2,3-diethynyl quinoxalines and 4-ethynyl-substituted pyrrolo[1,2-a]quinoxalines.

Ali Keivanloo1, Saeed Lashkari2, Mohammad Bakherad2, Mahsa Fakharian2, Sima Abbaspour2.   

Abstract

One palladium-catalyzed sequential coupling reactions were successfully used as a new protocol for the synthesis of unsymmetrical 2,3-diethynyl quinoxalines and 4-ethynyl-substituted pyrrolo[1,2-a]quinoxalines. The one-pot two coupling reactions of 2,3-dichloroquinoxaline, with two different terminal alkynes, under controlled conditions produced selectively unsymmetrical 2,3-diethynyl quinoxalines with high yields. When one of the two terminal alkynes was 3-propyne-1-ol, in the presence of secondary amines, cyclization occurred and 4-ethynyl-substituted pyrrolo[1,2-a]quinoxalines were successfully formed. All synthesized compounds were tested against the two bacterial strains including Micrococcus luteus and Pseudomonas aeruginosa.

Entities:  

Keywords:  Antibacterial activity; Coupling reactions; Propargyl alcohol; Pyrrolo[1,2-a]quinoxaline; Terminal alkyne

Year:  2020        PMID: 32301033     DOI: 10.1007/s11030-020-10083-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  17 in total

1.  Changing therapeutic paradigms in glaucoma management.

Authors:  R David
Journal:  Expert Opin Investig Drugs       Date:  1998-07       Impact factor: 6.206

2.  Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies.

Authors:  G Campiani; E Morelli; S Gemma; V Nacci; S Butini; M Hamon; E Novellino; G Greco; A Cagnotto; M Goegan; L Cervo; F Dalla Valle; C Fracasso; S Caccia; T Mennini
Journal:  J Med Chem       Date:  1999-10-21       Impact factor: 7.446

3.  New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity--Part II.

Authors:  Jean Guillon; Elisabeth Mouray; Stéphane Moreau; Catherine Mullié; Isabelle Forfar; Vanessa Desplat; Solene Belisle-Fabre; Noël Pinaud; François Ravanello; Augustin Le-Naour; Jean-Michel Léger; Grace Gosmann; Christian Jarry; Gérard Déléris; Pascal Sonnet; Philippe Grellier
Journal:  Eur J Med Chem       Date:  2011-03-15       Impact factor: 6.514

4.  Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure.

Authors:  G Campiani; A Cappelli; V Nacci; M Anzini; S Vomero; M Hamon; A Cagnotto; C Fracasso; C Uboldi; S Caccia; S Consolo; T Mennini
Journal:  J Med Chem       Date:  1997-10-24       Impact factor: 7.446

5.  New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity.

Authors:  Jean Guillon; Stéphane Moreau; Elisabeth Mouray; Véronique Sinou; Isabelle Forfar; Solene Belisle Fabre; Vanessa Desplat; Pascal Millet; Daniel Parzy; Christian Jarry; Philippe Grellier
Journal:  Bioorg Med Chem       Date:  2008-09-17       Impact factor: 3.641

6.  Efficient and stereoselective synthesis of yellow scale pheromone via alkyne haloboration, Zr-catalyzed asymmetric carboalumination of alkenes (ZACA reaction), and Pd-catalyzed tandem Negishi coupling.

Authors:  Zhaoqing Xu; Ei-Ichi Negishi
Journal:  Org Lett       Date:  2008-09-03       Impact factor: 6.005

7.  The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline.

Authors:  J Harmenberg; A Akesson-Johansson; A Gräslund; T Malmfors; J Bergman; B Wahren; S Akerfeldt; L Lundblad; S Cox
Journal:  Antiviral Res       Date:  1991 Mar-Apr       Impact factor: 5.970

Review 8.  Quinoxaline, its derivatives and applications: A State of the Art review.

Authors:  Joana A Pereira; Ana M Pessoa; M Natália D S Cordeiro; Rúben Fernandes; Cristina Prudêncio; João Paulo Noronha; Mónica Vieira
Journal:  Eur J Med Chem       Date:  2014-07-01       Impact factor: 6.514

9.  Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.

Authors:  Andrea Unzue; Jing Dong; Karine Lafleur; Hongtao Zhao; Emilie Frugier; Amedeo Caflisch; Cristina Nevado
Journal:  J Med Chem       Date:  2014-07-30       Impact factor: 7.446

10.  The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway.

Authors:  Khaled Ghattass; Sally El-Sitt; Kazem Zibara; Saide Rayes; Makhluf J Haddadin; Marwan El-Sabban; Hala Gali-Muhtasib
Journal:  Mol Cancer       Date:  2014-01-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.